Fumihiko Soeda1, Tadashi Watabe2, Sadahiro Naka3, Yuwei Liu1, Genki Horitsugi1, Oliver C Neels4, Klaus Kopka4,5, Mitsuaki Tatsumi6, Eku Shimosegawa7, Frederik L Giesel8,5, Jun Hatazawa1. 1. Department of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine, Osaka, Japan. 2. Department of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine, Osaka, Japan watabe@tracer.med.osaka-u.ac.jp. 3. Department of Pharmaceuticals, Osaka University Hospital, Osaka, Japan. 4. Division of Radiopharmaceutical Chemistry, German Cancer Research Center, Heidelberg, Germany. 5. German Cancer Consortium, Heidelberg, Germany. 6. Department of Radiology, Osaka University Hospital, Osaka, Japan. 7. Department of Molecular Imaging in Medicine, Osaka University Graduate School of Medicine, Osaka, Japan; and. 8. Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany.
Abstract
PET radioligands with low molar activity (MA) may underestimate the quantity of the target of interest because of competitive binding of the target with unlabeled ligand. The aim of this study was to evaluate the change in the whole-body distribution of 18F-PSMA-1007 targeting prostate-specific membrane antigen (PSMA) when solutions with different peptide concentrations are used. Methods: Mouse xenograft models of LNCaP (PSMA-positive prostate cancer) (n = 18) were prepared and divided into 3 groups according to the peptide concentration injected: a high-MA group (1,013 ± 146 GBq/μmol; n = 6), a medium-MA group (100.7 ± 23.1 GBq/μmol; n = 6), and a low-MA group (10.80 ± 2.84 GBq/μmol; n = 6). Static PET scans were performed 1 h after injection (scan duration, 10 min). SUVmean in tumor and normal organs was compared by the multiple-comparison test. Immunohistochemical staining and Western blot analysis were performed to confirm expression of PSMA in tumor, salivary gland, and kidney. Results: The low-MA group (SUVmean, 1.12 ± 0.30) showed significantly lower uptake of 18F-PSMA-1007 in tumor than did the high-MA group (1.97 ± 0.77) and the medium-MA group (1.81 ± 0.57). On the other hand, in salivary gland, both the low-MA group (SUVmean, 0.24 ± 0.04) and the medium-MA group (0.57 ± 0.08) showed significantly lower uptake than the high MA group (1.27 ± 0.28). The tumor-to-salivary gland SUVmean ratio was 1.73 ± 0.55 in the high-MA group, 3.16 ± 0.86 in the medium-MA group, and 4.78 ± 1.29 in the low-MA group. The immunohistochemical staining and Western blot analysis revealed significant overexpression of PSMA in tumor and low expression in salivary gland and kidney. Conclusion: A decrease in the MA level of the injected 18F-PSMA-1007 solution resulted in decreased uptake in tumor and, to a greater degree, in normal salivary gland. Thus, there is a possibility of minimizing the adverse effects in salivary gland by setting an appropriate MA level in PSMA-targeting therapy.
PET radioligands with low molar activity (MA) may underestimate the quantity of the target of interest because of competitive binding of the target with unlabeled ligand. The aim of this study was to evaluate the change in the whole-body distribution of 18F-PSMA-1007 targeting prostate-specific membrane antigen (PSMA) when solutions with different peptide concentrations are used. Methods:Mouse xenograft models of LNCaP (PSMA-positive prostate cancer) (n = 18) were prepared and divided into 3 groups according to the peptide concentration injected: a high-MA group (1,013 ± 146 GBq/μmol; n = 6), a medium-MA group (100.7 ± 23.1 GBq/μmol; n = 6), and a low-MA group (10.80 ± 2.84 GBq/μmol; n = 6). Static PET scans were performed 1 h after injection (scan duration, 10 min). SUVmean in tumor and normal organs was compared by the multiple-comparison test. Immunohistochemical staining and Western blot analysis were performed to confirm expression of PSMA in tumor, salivary gland, and kidney. Results: The low-MA group (SUVmean, 1.12 ± 0.30) showed significantly lower uptake of 18F-PSMA-1007 in tumor than did the high-MA group (1.97 ± 0.77) and the medium-MA group (1.81 ± 0.57). On the other hand, in salivary gland, both the low-MA group (SUVmean, 0.24 ± 0.04) and the medium-MA group (0.57 ± 0.08) showed significantly lower uptake than the high MA group (1.27 ± 0.28). The tumor-to-salivary gland SUVmean ratio was 1.73 ± 0.55 in the high-MA group, 3.16 ± 0.86 in the medium-MA group, and 4.78 ± 1.29 in the low-MA group. The immunohistochemical staining and Western blot analysis revealed significant overexpression of PSMA in tumor and low expression in salivary gland and kidney. Conclusion: A decrease in the MA level of the injected 18F-PSMA-1007 solution resulted in decreased uptake in tumor and, to a greater degree, in normal salivary gland. Thus, there is a possibility of minimizing the adverse effects in salivary gland by setting an appropriate MA level in PSMA-targeting therapy.
Authors: Sarah Piron; Jeroen Verhoeven; Emma De Coster; Benedicte Descamps; Ken Kersemans; Leen Pieters; Anne Vral; Christian Vanhove; Filip De Vos Journal: Sci Rep Date: 2021-11-19 Impact factor: 4.379
Authors: Youssra Allach; Amina Banda; Willemijn van Gemert; Michel de Groot; Yvonne Derks; Melline Schilham; Alexander Hoepping; Lars Perk; Martin Gotthardt; Marcel Janssen; James Nagarajah; Bastiaan M Privé Journal: Cancers (Basel) Date: 2022-04-21 Impact factor: 6.639
Authors: Sarah Piron; Jeroen Verhoeven; Jan Courtyn; Ken Kersemans; Benedicte Descamps; Leen Pieters; Anne Vral; Christian Vanhove; Filip De Vos Journal: Sci Rep Date: 2022-09-21 Impact factor: 4.996
Authors: Hsiou-Ting Kuo; Kuo-Shyan Lin; Zhengxing Zhang; Carlos F Uribe; Helen Merkens; Chengcheng Zhang; François Bénard Journal: J Nucl Med Date: 2020-08-28 Impact factor: 11.082